US pharma major Eli Lilly (NYSE: LLY) has entered into a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by biotech firm Nektar Therapeutics(Nasdaq: NKTR), sending the latter’s share surging as much as 10% in pre-market trading today.
NKTR-358, which achieved first human dose in Phase I clinical development in March of 2017, has the potential to treat a number of autoimmune and other chronic inflammatory conditions.
Financial terms of the transaction
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze